Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57


Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.

Kriegsmann K, Cremer M, Zgorzelski C, Harms A, Muley T, Winter H, Kazdal D, Warth A, Kriegsmann M.

Pathology. 2019 Apr;51(3):240-245. doi: 10.1016/j.pathol.2018.11.009. Epub 2019 Feb 21.


Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.

Adamo B, Ricciardi GRR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Caruso M, Tuccari G, Adamo V.

Oncotarget. 2019 Jan 25;10(8):917. doi: 10.18632/oncotarget.26650. eCollection 2019 Jan 25.


Use of immunohistochemical analysis of CK5/6, CK14, and CK34betaE12 in the differential diagnosis of solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia of the breast.

Maeda I, Tajima S, Kanemaki Y, Tsugawa K, Takagi M.

SAGE Open Med. 2018 Nov 9;6:2050312118811542. doi: 10.1177/2050312118811542. eCollection 2018.


The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.

Adamo B, Ricciardi GRR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Michele C, Tuccari G, Adamo V.

Oncotarget. 2017 Aug 16;8(44):76974-76986. doi: 10.18632/oncotarget.20293. eCollection 2017 Sep 29. Erratum in: Oncotarget. 2019 Jan 25;10(8):917.


[Expression of TTF-1, NapsinA, P63, CK5/6 in Lung Cancer and Its Diagnostic Values for Histological Classification].

Yu H, Li L, Liu D, Li WM.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2017 May;48(3):336-341. Chinese.


HBME1 expression in Warthin tumour: relationships to CK5/6, P63, BCL2 and WT1 expression and histogenesis.

Handra-Luca A.

J Clin Pathol. 2017 May;70(5):458-460. doi: 10.1136/jclinpath-2016-204281. Epub 2017 Feb 27. No abstract available.


CK5/6 expression based on morphological components in adenoid cystic carcinoma of the breast.

Wu H.

Pol J Pathol. 2017;68(4):352-353. doi: 10.5114/pjp.2017.73930. No abstract available.


[Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].

Niu F, Wang L, Zhang W, Lyu S, Niu Y.

Zhonghua Zhong Liu Za Zhi. 2015 Oct;37(10):749-52. Chinese.


[Expression of p63, p40 and CK5/6 in small cell lung cancer].

Zhang L, Hou L, Xie H, Dong Z, Wu W, Kong J, Chen G, Wu C.

Zhonghua Bing Li Xue Za Zhi. 2015 Sep;44(9):644-7. Chinese.


Expressions of Thyroid Transcription Factor-1, Napsin A, p40, p63, CK5/6 and Desmocollin-3 in Non-Small Cell Lung Cancer, as Revealed by Imprint Cytology Using a Malinol-Based Cell-Transfer Technique.

Kawai T, Tominaga S, Hiroi S, Kameda K, Ogata S, Nakashima H, Ozeki Y, Nakanishi K.

Acta Cytol. 2015;59(6):457-64. doi: 10.1159/000442659. Epub 2015 Dec 23.


Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis.

Ma Y, Fan M, Dai L, Kang X, Liu Y, Sun Y, Xiong H, Liang Z, Yan W, Chen K.

Thorac Cancer. 2015 May;6(3):288-95. doi: 10.1111/1759-7714.12181. Epub 2015 Apr 24.


Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.

Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC, Askin F, Gabrielson E, Li QK.

Clin Transl Med. 2015 Apr 21;4:16. doi: 10.1186/s40169-015-0057-2. eCollection 2015.


Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.

Sailer V, Lüders C, Kuhn W, Pelzer V, Kristiansen G.

Virchows Arch. 2015 Jul;467(1):67-70. doi: 10.1007/s00428-015-1766-z. Epub 2015 Apr 8.


The significance of combined CK5/6 and p63 immunohistochemistry in predicting the risks of subsequent carcinoma development in intraductal papilloma of the breast.

Yang Y, Suzuki K, Abe E, Li C, Uno M, Akiyama F, Yamauchi H, Kikuchi M, Ohde S, Deshpande G, Shibahara Y, Nakamura Y, Sasano H.

Pathol Int. 2015 Feb;65(2):81-8. doi: 10.1111/pin.12248. Epub 2015 Jan 8.


Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, Johnson N, McDuffus LA, Miller J, Sawyer EJ, Pinder S, van Deurzen CH, Jones L, Sironen R, Visscher D, Caldas C, Daley F, Coulson P, Broeks A, Sanders J, Wesseling J, Nevanlinna H, Fagerholm R, Blomqvist C, Heikkilä P, Ali HR, Dawson SJ, Figueroa J, Lissowska J, Brinton L, Mannermaa A, Kataja V, Kosma VM, Cox A, Brock IW, Cross SS, Reed MW, Couch FJ, Olson JE, Devillee P, Mesker WE, Seyaneve CM, Hollestelle A, Benitez J, Perez JI, Menéndez P, Bolla MK, Easton DF, Schmidt MK, Pharoah PD, Sherman ME, García-Closas M.

J Pathol Clin Res. 2014 Dec 4;1(1):18-32. doi: 10.1002/cjp2.3. eCollection 2015 Jan.


Evaluation of napsin A, TTF-1, p63, p40, and CK5/6 immunohistochemical stains in pulmonary neuroendocrine tumors.

Zhang C, Schmidt LA, Hatanaka K, Thomas D, Lagstein A, Myers JL.

Am J Clin Pathol. 2014 Sep;142(3):320-4. doi: 10.1309/AJCPGA0IUA8BHQEZ.


ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens.

Zhao W, Wang H, Peng Y, Tian B, Peng L, Zhang DC.

Int J Clin Exp Pathol. 2014 Jun 15;7(7):4247-53. eCollection 2014.


Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast.

Wang J, Zhang X, He J, Yang M, Tang J, Li X, Tang H, Xie X.

Med Oncol. 2014 Sep;31(9):172. doi: 10.1007/s12032-014-0172-8. Epub 2014 Aug 15.


Supplemental Content

Support Center